The shadow of generic rivalry has repeatedly loomed above copyright’s blockbuster drug, Sildenafil, raising questions about the outlook of similar drug portfolios. While first times saw substantial gains, the https://pharma878800.blogscribble.com/42139553/the-copyright-and-the-pharmaceutical-industry-a-risky-opportunity